AOBI Stock Overview
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
American Oriental Bioengineering, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.0005 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -97.50% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AOBI | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.2% |
| 1Y | n/a | -26.0% | 24.9% |
Return vs Industry: Insufficient data to determine how AOBI performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how AOBI performed against the US Market.
Price Volatility
| AOBI volatility | |
|---|---|
| AOBI Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AOBI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AOBI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Tony Liu | n/a |
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis.
American Oriental Bioengineering, Inc. Fundamentals Summary
| AOBI fundamental statistics | |
|---|---|
| Market cap | US$36.00 |
| Earnings (TTM) | -US$91.02m |
| Revenue (TTM) | US$121.58m |
0.0x
P/S Ratio0.0x
P/E RatioIs AOBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AOBI income statement (TTM) | |
|---|---|
| Revenue | US$121.58m |
| Cost of Revenue | US$84.32m |
| Gross Profit | US$37.26m |
| Other Expenses | US$128.28m |
| Earnings | -US$91.02m |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AOBI perform over the long term?
See historical performance and comparison